DNA Vector Production via Recombinase-Mediated Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral gene delivery systems face challenges such as cellular barriers, immune responses, and degradation of DNA vectors, leading to inefficient gene expression and safety concerns, particularly with the presence of bacterial sequences in plasmid DNA vectors.
Innovation Solution
A novel in vivo vector production system using recombinant cells designed to express specific recombinases under inducible promoters, which produce circular or linear covalently closed vectors devoid of bacterial sequences, enhancing bioavailability and immuno-compatibility by leveraging bacteriophage-derived recombination systems like TelN and Cre.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional plasmid DNA vectors are used for non-viral gene delivery, then ease of manufacture and design capacity are improved, but safety and immuno-compatibility deteriorate due to presence of bacterial genetic elements
Solution Approach 1:
The patent extracts and removes harmful bacterial genetic elements (prokaryotic origins of replication, antibiotic resistance genes, CpG motifs) from plasmid DNA vectors while retaining the essential eukaryotic expression cassette, creating mini plasmid vectors that are safer for in vivo use
Solution Approach 2:
The patent segments the plasmid DNA into minimal essential components (eukaryotic expression cassette) and non-essential bacterial components (origin of replication, antibiotic resistance genes), keeping only the necessary segments for gene expression while discarding harmful elements
2Productivity
If plasmid DNA vectors are delivered to target cells, then gene delivery is achieved, but degradation by serum nucleases occurs rapidly leading to poor transfection efficiency
Solution Approach 1:
The patent applies preliminary protective actions by complexing plasmid DNA with cationic lipids or polymers to form lipoplexes or polyplexes before delivery, creating protective structures that prevent nuclease degradation during circulation and cellular uptake
Solution Approach 2:
The patent creates composite delivery systems by combining plasmid DNA with lipids or polymers to form lipoplexes or polyplexes, where the lipid or polymer component provides protection against nucleases while facilitating cellular uptake and delivery
3Productivity
If viral vectors are used for gene delivery, then transfection efficiency is improved, but safety deteriorates due to immune responses and insertional mutagenesis
Solution Approach 1:
The patent converts the limitations of non-viral vectors (poor transfection efficiency) into benefits by using chemically synthesized DNA with optimized sequences and structures that achieve both high transfection efficiency and safety, eliminating the need for viral components that cause immune responses
4Manufacturing precision
If linear covalently closed DNA vectors are produced via multistep in vitro processes, then vector purity is improved, but production time and cost increase considerably
Solution Approach 1:
The patent merges multiple separate purification steps into a single streamlined process by using site-specific recombination systems that directly produce pure linear covalently closed DNA vectors from plasmid templates, eliminating intermediate purification steps
Solution Approach 2:
The patent performs preliminary site-specific recombination reactions in vitro using purified recombinases and specific DNA sequences to directly generate linear covalently closed DNA vectors with covalently sealed ends, achieving high purity in a single reaction step
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in improved transfection efficiency, reduced toxicity, and enhanced gene expression by producing mini vectors that are safer and more immunocompatible, with superior bioavailability and lower immunogenicity, addressing the limitations of traditional plasmid DNA vectors.
Implementation Method 1
conventional non-viral gene delivery approaches may lead to unwanted immunological responses and oncogenesis, imparted by the presence of bacterial genetic elements in pDNA constructs. These include prokaryotic origins of replication, antibiotic resistance genes, as well as high-frequency immunostimulatory CpG motifs that activate Toll-like receptors in mammalian hosts. In order to improve the immuno-compatibility and durability of pDNA vectors, a new generation of plasmid vector has been constructed that exploit the bacteriophage λ derived integrase (Int)-attP or P1-derived Cre-loxP site-specific recombination systems to generate mini plasmids.
Implementation Method 2
E. coli phage N15 was the first discovered temperate phage that does not integrate into its bacterial host genome in its lysogenic (prophage) state and instead exists as a linear covalently closed (Icc)plasmid that is actively partitioned to daughter cells. The Icc conformation is conferred by the cleaving-joining activity of the protelomerase protein (Prokaryotic Telomerase), TelN (̃72 kDa), acting upon the 56 bp telRL target sequence that is entirely sufficient to confer TelN-mediated processing and linearization both in vivo and in vitro.
Data Source
AI summary
A vector production system is provided. The system comprises recombinant cells designed to encode at least a first recombinase under the control of an inducible promoter and the cells include an expression vector encoding a nucleic acid of interest within the regulatory elements of the expression vector which are flanked on either side by a target sequence for at least the first recombinase. The vector production system provides an efficient one-step process for producing linear or circular covalently closed vectors that incorporate a nucleic acid sequence of interest.